Sanofi Current Ratio 1999-2025 | SNY

Current and historical current ratio for Sanofi (SNY) from 1999 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Sanofi current ratio for the three months ending June 30, 2025 was 1.27.
Sanofi Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2025-06-30 $42.02B $32.99B 1.27
2025-03-31 $46.37B $33.95B 1.37
2024-12-31 $46.08B $31.56B 1.46
2024-09-30 $0.00B 0.00
2024-06-30 $32.39B $32.34B 1.00
2024-03-31 $0.00B 0.00
2023-12-31 $33.19B $26.19B 1.27
2023-09-30 $0.00B 0.00
2023-06-30 $32.69B $27.00B 1.21
2023-03-31 $0.00B 0.00
2022-12-31 $35.85B $25.25B 1.42
2022-09-30 $0.00B 0.00
2022-06-30 $30.18B $23.48B 1.29
2022-03-31 $0.00B 0.00
2021-09-30 $0.00B 0.00
2021-06-30 $35.55B $23.05B 1.54
2021-03-31 $0.00B 0.00
2020-09-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $29.79B $17.47B 1.71
2017-09-30 $0.00B 0.00
2017-06-30 $29.78B $18.76B 1.59
2017-03-31 $0.00B 0.00
2016-12-31 $29.53B $18.19B 1.62
2016-09-30 $0.00B 0.00
2016-06-30 $25.23B $17.22B 1.47
2016-03-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $24.35B $18.03B 1.35
2014-06-30 $27.94B $19.48B 1.43
2013-06-30 $27.17B $17.80B 1.53
2012-06-30 $27.56B $20.66B 1.33
2012-03-31 $0.00B 0.00
2011-12-31 $29.05B $18.92B 1.54
2011-09-30 $0.00B 0.00
2011-06-30 $32.57B $23.10B 1.41
2011-03-31 $0.00B 0.00
2010-12-31 $35.96B $15.62B 2.30
2010-09-30 $0.00B 0.00
2010-06-30 $31.89B $15.40B 2.07
2010-03-31 $0.00B 0.00
2009-12-31 $33.30B $17.29B 1.93
2009-09-30 $0.00B 0.00
2009-06-30 $25.23B $14.69B 1.72
2009-03-31 $0.00B 0.00
2008-12-31 $22.66B $13.75B 1.65
2008-09-30 $0.00B 0.00
2008-06-30 $18.62B $14.01B 1.33
2008-03-31 $0.00B 0.00
2007-12-31 $17.21B $13.25B 1.30
2007-09-30 $0.00B 0.00
2007-06-30 $16.75B $13.18B 1.27
2007-03-31 $0.00B 0.00
2006-12-31 $15.28B $12.91B 1.18
2006-09-30 $0.00B 0.00
2006-06-30 $15.45B $17.89B 0.86
2006-03-31 $0.00B 0.00
2005-12-31 $16.34B $19.20B 0.85
2005-09-30 $0.00B 0.00
2005-06-30 $16.55B $20.53B 0.81
2005-03-31 $0.00B 0.00
2004-12-31 $15.58B $18.67B 0.84
2004-06-30 $8.52B $3.44B 2.48
2003-12-31 $8.86B $3.27B 2.72
2003-06-30 $6.31B $2.72B 2.32
2002-12-31 $6.37B $2.67B 2.39
2002-06-30 $5.58B $2.42B 2.30
2001-12-31 $6.38B $2.66B 2.40
2001-06-30 $5.02B $1.91B 2.63
2000-12-31 $5.05B $2.11B 2.39
1999-12-31 $4.65B $2.23B 2.09
1998-12-31 $4.26B $2.29B 1.86
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $132.955B $45.310B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Innoviva (INVA) United States $0.953B 10.12